

## Introduction

WANDA REYGAERT

INDEX TERMS: MRSA, methicillin-resistance, *Staphylococcus aureus*

Clin Lab Sci 2009;22(2); 109

Wanda Reygaert PhD is assistant professor, Medical Laboratory Science Program, Oakland University, Rochester, MI.

Address for Correspondence: Wanda Reygaert, PhD, Assistant Professor, Oakland University, School of Health Sciences, Medical Laboratory Science Program, Rochester, Michigan 48309, reygaert@oakland.edu

Wanda Reygaert PhD is the Focus: Methicillin-Resistant *Staphylococcus aureus* guest editor.

*Staphylococcus aureus* is a non-motile, gram-positive cocci that colonizes in clusters. It is found world wide and is a leading cause of disease. It can normally only transiently colonize the outside and entry portals of the human body (skin, ears, eye, nasal passages, etc.), but it is estimated that 20% of humans are carriers (asymptomatic permanent colonization)<sup>1</sup>. However, even transient colonization can lead to infection if the conditions are right; such as a breach in the protective layer of epithelial cells, or a compromised immune system. The ability to cause disease is via two mechanisms: 1) toxin production, and/or 2) proliferation of the organism, which causes tissue destruction.


Most infections remain localized at entry portals and are usually self-limiting and non-life threatening. Much less

frequently, more serious infections may occur when the organism is able to invade deeper into the body (osteomyelitis, septicemia, pneumonia, etc.) (Fig. 1). These deeper infections may be extremely serious and even fatal. Because infections of *S. aureus* occur at a higher rate than that of many bacteria, the costs that are incurred for hospitalization and treatment can be tremendous. In just one year, 1995, in New York City, it was estimated that there were at least 13,550 cases of *S. aureus* infections resulting in an estimated cost of about \$435.5 million<sup>2</sup>.

In a study that was published in 2007 with data from the year 2003, it was found that nearly 390,000 people in the U.S. were hospitalized with *S. aureus* infections, with the average hospital stay for this type of infection costing \$37,251. The total cost of *S. aureus* infections in the U.S. for 2003 was \$14.5 billion<sup>3</sup>.

Before the advent of antibiotics the mortality rate from *S. aureus* infections was near 80%. When penicillin therapy was introduced in the 1940s, it seemed that *S. aureus* (along with many other bacteria) infections could now be easily treated. However, within a short amount of time penicillin-resistant *S. aureus* had appeared, with approximately 80% of *S. aureus* now being penicillin resistant<sup>4</sup>. This led to the discovery and use of other antimicrobials such as methicillin in the 1960s.

Figure 1. Infections caused by *Staphylococcus aureus*



The Focus section seeks to publish relevant and timely continuing education for clinical laboratory practitioners. Section editors, topics, and authors are selected in advance to cover current areas of interest in each discipline. Readers can obtain continuing education credit (CE) through P.A.C.E.® by completing the continuing education registration form, recording answers to the examination, and mailing a photocopy of it with the appropriate fee to the address designated on the form. Suggestions for future Focus topics and authors, and manuscripts appropriate for CE credit are encouraged. Direct all inquiries to the Clin Lab Sci Editorial Office, Westminster Publishers, 315 Westminster Court, Brandon MS 39047. (601) 214-5028, (202) 315-5843 (fax). westminsterpublishers@comcast.net.

Once again, the organism seemed to be under control. It wasn't long however, before methicillin-resistant *S. aureus* (MRSA) appeared, and strains that were sensitive to methicillin became known as MSSA (methicillin-susceptible *S. aureus*)<sup>5</sup>. Then clinicians turned to the use of Vancomycin for serious MRSA infections, and recently we have seen that MRSA strains are evolving that are able to overcome Vancomycin. A few Vancomycin-Intermediate Resistant *S. aureus* (VISA) have been isolated (Fig. 2)<sup>6</sup>. It seems that it's only a matter of time before we will be faced with full-blown Vancomycin-Resistant *S. aureus* (VRSA). At that point what will we be able to use to fight it?

MRSA is now a significant cause of infections worldwide. It has been estimated that in the U.S. over 126,000 hospitalized people become infected with MRSA each year. Over 5,000 patients die from these infections which cost the U.S. over \$2.5 billion per year, and result in an average of \$20,000 in excess cost per case of MRSA infection<sup>7</sup>. There has also been a dramatic increase in the prevalence of community-acquired MRSA, which is now thought to be responsible for up to 74% of skin and soft tissue infections acquired outside of the hospital<sup>8</sup>.

Since methicillin was found to have limited therapeutic value and sometimes had serious side effects, usage in the U.S. was discontinued, and it is

now unavailable for resistance testing. A closely related antimicrobial, oxacillin, has replaced methicillin in actual resistance testing, so MRSA may also be referred to as oxacillin-resistant *Staphylococcus aureus* (ORSA) in some sources, especially in articles not written in the U.S.<sup>9, 10</sup>.

This series of articles is designed to provide a general well-rounded knowledge of MRSA. The second article in the series will delve into the prevalence and epidemiology of MRSA, showing how serious a problem it has become since the advent of antibiotics. The third article will cover the pathogenesis and virulence of the organism as well as the molecular basis of some antimicrobial resistance issues. The last article will explain how MRSA is identified, by manual and automated methods, including traditional and more modern methods, and will discuss what antimicrobial therapy options may now be available.

## REFERENCES

1. Kluytmans J, Van Belkum A, Verbrugh H. Nasal carriage of *Staphylococcus aureus*: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev 1997; 10:505–20.
2. Rubin RJ, Harrington CA, Poon A, Dietrich K, Greene JA, Moiduddin A. The economic impact of *Staphylococcus aureus* infection in New York City hospitals. Emerg Infect Dis 1999; 5:9–17.
3. Noskin GA, Rubin RJ, Schentag JJ, et al. National trends in *Staphylococcus aureus* infection rates: impact on economic

burden and mortality over a 6-year period (1998-2003). Clin Infect Dis 2007; 45:1132–40.

4. Deurenberg RH, Vink C, Kalenic S, et al. The molecular evolution of methicillin-resistant *Staphylococcus aureus*. Clin Microbiol Infect 2007; 13:222–35.
5. Chambers HF. The changing epidemiology of *Staphylococcus aureus*? Emerg Infect Dis 2001; 7:17–82.
6. Smith TL, Pearson ML, Wilcox KR, et al., for the Glycopeptide-Intermediate *Staphylococcus aureus* Working Group. Emergence of vancomycin resistance in *Staphylococcus aureus*. N Engl J Med 1999; 340:493–501.
7. Institute for Healthcare Improvement. Protecting 5 Million Lives From Harm. <http://www.ihl.org/IHI/Programs/Campaign/>. December 2006.
8. Boyce JM. Community-associated methicillin-resistant *Staphylococcus aureus* as a cause of health care-associated infection. Clin Infect Dis 2008; 46:795–8.
9. Gosbell IB, Mercer JL, Neville SA, et al. Community-acquired, non-multiresistant oxacillin-resistant *Staphylococcus aureus* (NORSA) in South Western Sydney. Pathology 2001; 33:206–10.
10. Rello J, Sole-Violan J, Sa-Borges M, et al. Pneumonia caused by oxacillin-resistant *Staphylococcus aureus* treated with glycopeptides. Crit Care Med 2005; 33:1983–7.

**Figure 2.** Timeline of the Development of Antibiotic Resistance in *Staphylococcus aureus*

